Sanofi-Aventis and Genzyme Corp. have reached a definitive agreement under which Sanofi will acquire Genzyme for approximately $20.1 billion in cash. Genzyme shareholders are also eligible to receive additional milestone payments related to Lemtrada (alemtuzumab MS), or a milestone related to 2011 production volumes for Cerezyme and Fabrazyme. The transaction is expected to close early in 2Q11, subject to customary closing conditions. “This agreement with Genzyme is both consistent with our ...